Related Experiment Videos
Multiple functions of type 10 17beta-hydroxysteroid dehydrogenase.
Song-Yu Yang1, Xue-Ying He, Horst Schulz
1Department of Pharmacology, New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY 10314, USA. yang.songyu@yahoo.com
Trends in Endocrinology and Metabolism: TEM
|April 30, 2005
Summary
Human 17beta-hydroxysteroid dehydrogenase type 10 (17beta-HSD10) is a mitochondrial enzyme linked to neurodegeneration and cancer. Its role in metabolism and hormone conversion suggests potential as a drug target for Alzheimer's disease and prostate cancer.
Area of Science:
- Biochemistry
- Enzymology
- Neuroscience
Background:
- 17beta-hydroxysteroid dehydrogenase type 10 (17beta-HSD10), encoded by the SCHAD gene, is a mitochondrial enzyme.
- Mutations in 17beta-HSD10/SCHAD are associated with neurodevelopmental disorders and neurodegeneration.
- The enzyme plays a role in isoleucine metabolism and steroid hormone conversion.
Purpose of the Study:
- To investigate the multifaceted roles of 17beta-HSD10 in cellular metabolism and disease.
- To explore the potential of 17beta-HSD10 as a therapeutic target for neurological disorders and cancer.
Main Methods:
- Enzyme activity assays.
- Genetic mutation analysis.
- Substrate specificity studies.
- Analysis of 17beta-HSD10 expression in cancer cells.
Main Results:
- 17beta-HSD10 is crucial for isoleucine and branched-chain fatty acid metabolism.
- The enzyme converts 5alpha-androstanediol to 5alpha-dihydrotestosterone (DHT), a process elevated in some prostate cancers.
- 17beta-HSD10 binds to amyloid-beta peptide, suggesting a link to Alzheimer's disease pathology.
- 17beta-HSD10 modulates GABA(A) receptors.
Conclusions:
- 17beta-HSD10 is a versatile enzyme with implications in neurodegeneration, Alzheimer's disease, and prostate cancer.
- Targeting 17beta-HSD10 may offer therapeutic strategies for controlling neuronal excitability and treating these conditions.